drugset / Trial / NCT01165632

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

NCT01165632

Phase 0 Completed 24 enrolled Mayo Clinic
NaSingle-groupOpen-labelDiagnostic

Summary

RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma

Timeline

Start
2010-07-26
Primary completion
2013-11-05
Completion
2019-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-DOPA Diagnostic / imaging agent Intravenous